The following is a summary of “Longitudinal assessment of immunoglobulin response and disease progression in critically ill ...

Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...

“The cumulative incidence of non-relapse mortality [14% at 3 years] reflects how heavily pretreated this cohort was,” Dr Kramer said. Immunoglobulin G replacement therapy was “essential” for most ...